Evidence map›Paper›PMID 37003701›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2023

Designing Covalent Organic Framework-Based Light-Driven Microswimmers toward Therapeutic Applications.

Varun Sridhar, Erdost Yildiz, Andrés Rodríguez-Camargo, Xianglong Lyu, Liang Yao, Paul Wrede, Amirreza Aghakhani, Birgul M Akolpoglu, Filip Podjaski, Bettina V Lotsch and 1 more

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Magnetically Controllable and Degradable Milliscale Swimmers as Intraocular Drug Implants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  9. MOF Coating Enhances the Ion Tolerance of Micromotors.Angewandte Chemie (International ed. in English) · 2025
    Article
  10. Review
  11. Article
  12. Microrobotic Swarms for Cancer Therapy.Research (Washington, D.C.) · 2025
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Varun SridharPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, 70569, Stuttgart, Germany.ORCID https://orcid.org/0000-0003-3081-952X
Erdost YildizPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, 70569, Stuttgart, Germany.ORCID https://orcid.org/0000-0001-8086-3524
Andrés Rodríguez-CamargoNanochemistry Department, Max Planck Institute for Solid State Research, 70569, Stuttgart, Germany.
Xianglong LyuPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, 70569, Stuttgart, Germany.
Liang YaoNanochemistry Department, Max Planck Institute for Solid State Research, 70569, Stuttgart, Germany.
Paul WredePhysical Intelligence Department, Max Planck Institute for Intelligent Systems, 70569, Stuttgart, Germany.
Amirreza AghakhaniPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, 70569, Stuttgart, Germany.
Birgul M AkolpogluPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, 70569, Stuttgart, Germany.
Filip PodjaskiNanochemistry Department, Max Planck Institute for Solid State Research, 70569, Stuttgart, Germany.
Bettina V LotschNanochemistry Department, Max Planck Institute for Solid State Research, 70569, Stuttgart, Germany.ORCID https://orcid.org/0000-0002-3094-303X
Metin SittiPhysical Intelligence Department, Max Planck Institute for Intelligent Systems, 70569, Stuttgart, Germany.ORCID https://orcid.org/0000-0001-8249-3854

Funding

Deutsche Forschungsgemeinschaft EXC2089/1-390776260European Union's Horizon 2020 research and innovation programMarie Skłodowska-Curie 101059593UKRI EP/X027449/1
6 · The paper itself

Abstract

While micromachines with tailored functionalities enable therapeutic applications in biological environments, their controlled motion and targeted drug delivery in biological media require sophisticated designs for practical applications. Covalent organic frameworks (COFs), a new generation of crystalline and nanoporous polymers, offer new perspectives for light-driven microswimmers in heterogeneous biological environments including intraocular fluids, thus setting the stage for biomedical applications such as retinal drug delivery. Two different types of COFs, uniformly spherical TABP-PDA-COF sub-micrometer particles and texturally nanoporous, micrometer-sized TpAzo-COF particles are described and compared as light-driven microrobots. They can be used as highly efficient visible-light-driven drug carriers in aqueous ionic and cellular media. Their absorption ranging down to red light enables phototaxis even in deeper and viscous biological media, while the organic nature of COFs ensures their biocompatibility. Their inherently porous structures with ≈2.6  and ≈3.4 nm pores, and large surface areas allow for targeted and efficient drug loading even for insoluble drugs, which can be released on demand. Additionally, indocyanine green (ICG) dye loading in the pores enables photoacoustic imaging, optical coherence tomography, and hyperthermia in operando conditions. This real-time visualization of the drug-loaded COF microswimmers enables unique insights into the action of photoactive porous drug carriers for therapeutic applications.

Indexed as

Metal-Organic FrameworksAqueous HumorDrug CarriersDrug Delivery SystemsPolymersDrug CarriersMetal-Organic FrameworksPolymerscovalent organic frameworkslight-driven systemsmicroswimmersoptical coherence tomographytargeted drug delivery

Identifiers

PMID37003701
PMCPMC11475396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.